about
New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle functionOn the metabolically active form of metaglidasen: improved synthesis and investigation of its peculiar activity on peroxisome proliferator-activated receptors and skeletal musclesSplicing of the rSlo gene affects the molecular composition and drug response of Ca2+-activated K+ channels in skeletal muscleDifferent ability of clenbuterol and salbutamol to block sodium channels predicts their therapeutic use in muscle excitability disorders.Pre-clinical trials in Duchenne dystrophy: what animal models can tell us about potential drug effectiveness.Therapeutic approaches to ion channel diseases.Mechanisms of block of muscle type CLC chloride channels (Review).Taurine and skeletal muscle disorders.Adaptation of mouse skeletal muscle to long-term microgravity in the MDS missionHydroxylated analogs of mexiletine as tools for structural-requirements investigation of the sodium channel blocking activity.Molecular determinants of differential pore blocking of kidney CLC-K chloride channels.Structural requisites of 2-(p-chlorophenoxy)propionic acid analogues for activity on native rat skeletal muscle chloride conductance and on heterologously expressed CLC-1.Searching for novel anti-myotonic agents: pharmacophore requirement for use-dependent block of skeletal muscle sodium channels by N-benzylated cyclic derivatives of tocainide.Disuse of rat muscle in vivo reduces protein kinase C activity controlling the sarcolemma chloride conductance.Combined modifications of mexiletine pharmacophores for new lead blockers of Na(v)1.4 channels.Functional characterization of ClC-1 mutations from patients affected by recessive myotonia congenita presenting with different clinical phenotypes.Is oxidative stress a cause or consequence of disuse muscle atrophy in mice? A proteomic approach in hindlimb-unloaded mice.A large cohort of myotonia congenita probands: novel mutations and a high-frequency mutation region in exons 4 and 5 of the CLCN1 gene.Molecular requisites for drug binding to muscle CLC-1 and renal CLC-K channel revealed by the use of phenoxy-alkyl derivatives of 2-(p-chlorophenoxy)propionic acid.Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1.N-aryl-2,6-dimethylbenzamides, a new generation of tocainide analogues as blockers of skeletal muscle voltage-gated sodium channels.Decrease in resting calcium and calcium entry associated with slow-to-fast transition in unloaded rat soleus muscle.Optimal requirements for high affinity and use-dependent block of skeletal muscle sodium channel by N-benzyl analogs of tocainide-like compounds.Different flecainide sensitivity of hNav1.4 channels and myotonic mutants explained by state-dependent block.Optically active mexiletine analogues as stereoselective blockers of voltage-gated Na(+) channels.Investigations of pharmacologic properties of the renal CLC-K1 chloride channel co-expressed with barttin by the use of 2-(p-Chlorophenoxy)propionic acid derivatives and other structurally unrelated chloride channels blockers.Stereospecific synthesis of "para-hydroxymexiletine" and sodium channel blocking activity evaluation.New potent mexiletine and tocainide analogues evaluated in vivo and in vitro as antimyotonic agents on the myotonic ADR mouse.Synthesis and in vitro sodium channel blocking activity evaluation of novel homochiral mexiletine analogs.Gentamicin treatment in exercised mdx mice: Identification of dystrophin-sensitive pathways and evaluation of efficacy in work-loaded dystrophic muscle.Fiber type-related changes in rat skeletal muscle calcium homeostasis during aging and restoration by growth hormone.Constrained analogues of tocainide as potent skeletal muscle sodium channel blockers towards the development of antimyotonic agents.Synthesis and toxicopharmacological evaluation of m-hydroxymexiletine, the first metabolite of mexiletine more potent than the parent compound on voltage-gated sodium channels.Activation and inhibition of kidney CLC-K chloride channels by fenamates.Paving the way for Bartter syndrome type 3 drug discovery: a hope from basic research.In-vivo administration of CLC-K kidney chloride channels inhibitors increases water diuresis in rats: a new drug target for hypertension?Fluvastatin and atorvastatin affect calcium homeostasis of rat skeletal muscle fibers in vivo and in vitro by impairing the sarcoplasmic reticulum/mitochondria Ca2+-release system.Overactivity of exercise-sensitive cation channels and their impaired modulation by IGF-1 in mdx native muscle fibers: beneficial effect of pentoxifylline.Pharmacology of CLC Chloride Channels and TransportersOptically Active Mexiletine Analogues as Stereoselective Blockers of Voltage-Gated Na+Channels
P50
Q27657537-CDB847D4-E793-4914-BE12-717673863411Q27697692-DF2E23BA-8C47-4E6C-ADB9-1187826FFAB9Q28481241-02A9837B-5B1A-462B-A502-070D3CB09E7EQ34180008-6A002518-599B-4770-AF5B-E65730BD0CABQ34807169-AC2FDBE6-E85C-40C2-95ED-FEA4CB784BA1Q34927551-7979A0D4-8744-43E4-9C0D-3786D0E2B0A2Q35038948-9290A667-EF6F-472C-9A3F-E4DE78CEA52BQ35678828-FC74A366-5913-4B19-A257-BEC09F87A3F3Q35858592-ED06A9C7-055D-4D61-96DD-0B4DB0493C82Q39699167-A5511D40-5B38-4D7E-ABAF-84A92AC86F57Q40102720-7D7D12D9-1564-473E-9929-181B286E1B0AQ42019489-28CF3882-9E91-47D9-B791-69F3CADFCA8AQ42080376-BE87939A-6B09-461C-9E7C-6FC5C5208E52Q42518795-D2926939-AE91-40AA-A9A1-85A27FEDC002Q42928982-596ECCCD-2AB6-4E3D-B402-D15DC7BE6441Q42970603-D8CEEE04-DD3D-4F38-9CDD-C7598E2ABC1CQ43263806-8B477A4A-B35B-46B1-BE00-3A9842D095E7Q43774424-0662B1FF-6AD0-4584-8C91-8AA24B491058Q44072155-0CCA9402-53BF-4BD9-A623-AA0D7F87A053Q44255035-42F1D16E-ABBC-4F5E-A844-0CE81823E368Q44489520-090806AA-F45D-481F-B1E9-02C08F237BD7Q44552025-37E78CB5-9F37-46C4-BC3F-0AACC55ABA23Q44590880-1CAA970B-4292-4C38-A567-61BAE5DCD528Q44649200-0830902A-557A-4EE5-BB09-6B89AA8CFD2BQ44652632-31CF9431-D9D7-41ED-80B5-2E8F3465BC05Q44705255-A325F78D-11E9-41CE-85FB-3DF44F262B9DQ44719904-598FFDDC-2D86-47D6-AE31-1797F8FD1B87Q44946695-E46686E0-F3C9-4B14-B5CB-9B313002EFD3Q45959411-18102771-EF82-4A17-BAE7-552BEE55BF4EQ46434974-B5A5D7E2-CF57-45E7-82F1-68A58C6763C2Q46695631-4745B8B3-36D5-499E-AFE6-0B7A88E537F9Q46700912-0DC372AA-DB8A-49BD-A246-ED847BB0DA87Q46702840-4CD3F05F-51D4-4F10-92E2-1E0A43CC42FEQ46769844-2C4843FB-242D-4394-96FD-A1A00D1ECA5AQ47574227-C852CC35-A3BF-4394-8E29-9EA7E7A6679FQ47574341-40863287-A369-4065-A3ED-874999594AA5Q50705628-7F5A5650-13CE-4463-9CFC-9E1B44B8C3F8Q50719694-780D164B-51D9-4CC2-81DC-6152C8AA61BBQ59467086-82975D08-58E4-4862-85DB-44F5CDCA9F9DQ59467111-C3B2000E-EA78-47FE-8463-65E16380FE13
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Diana Conte Camerino
@ast
Diana Conte Camerino
@en
Diana Conte Camerino
@es
Diana Conte Camerino
@nl
Diana Conte Camerino
@sl
type
label
Diana Conte Camerino
@ast
Diana Conte Camerino
@en
Diana Conte Camerino
@es
Diana Conte Camerino
@nl
Diana Conte Camerino
@sl
altLabel
Diana C Camerino
@en
Diana Conte Camerino
@en
prefLabel
Diana Conte Camerino
@ast
Diana Conte Camerino
@en
Diana Conte Camerino
@es
Diana Conte Camerino
@nl
Diana Conte Camerino
@sl
P106
P1153
7005038891
P21
P31
P496
0000-0003-0162-9698